Gastroenterology · Phase 2
Ipamorelin: gastrointestinal recovery after surgery
What was tested?
Intravenous ipamorelin versus placebo after bowel-resection surgery. ↗
Registered primary question: Recovery of gastrointestinal function, assessed daily until hospital discharge. ↗
What the reviewed report found
Journal year 2014 · Article summary reviewed 2026-09-15
Time to a tolerated solid meal was not significantly different between groups. Treatment-emergent adverse events occurred in 87.5% with ipamorelin and 94.8% with placebo.↗
Keep in context: The report describes 117 enrolled and 114 in safety and modified intention-to-treat analyses. The primary efficacy difference was not statistically significant; this route and setting do not establish effects for other proposed uses. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 117 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Parallel
- Eligible ages
- 18 Years to 85 Years
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2017-04-14; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Postoperative ileus: a placebo-controlled phase 2 trial
- Design in the report
- A multicenter blinded randomized placebo-controlled study assessed recovery after bowel resection.↗
- Participants in the report
- The trial enrolled 117 adults; 114 were included in its safety and modified intent-to-treat populations.↗
- Limitations
- The study was small and included varied underlying conditions. A nonsignificant result does not prove equivalence, and these postoperative findings do not establish safety for other uses or routes.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus ↗
Protocol identifier: ST-IPAM-201. Sponsor: Helsinn Therapeutics (U.S.), Inc.
Retrieved 2026-09-20; SHA-256 8c21e45194bd90e09f4809ac85e21e0c5fee20431caad2a4fdf3a15d026e7a3c.
PMID 25331030
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 25331030. SHA-256 b9b2737876819a52052ecd9dc7208be1ad5712f7a133c5c13d04f6663f02d118.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 f433760c65427acf99c62a5d9a61fcfba84fbb3c078f210883e5bf48385c2048.